Mohamed Amgad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohamed Amgad has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Lee Alex Donald Cooper
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
21 shared publications Hagar Hussein
12 shared publications- David A. Gutman
Emory University, Department of Pathology, GA, USA
10 shared publications Habiba Elfandy
10 shared publications- Pooya Mobadersany
Janssen Research & Development, New Brunswick, NJ
10 shared publications Brian P. Pollack
9 shared publications
Latest Publications
- 24 April 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (7) , 1686-1693
Long-Term Multifocal Pulmonary Fibrosis Associated with Y-90 Embolization: A Case Report and Literature Review
Radioembolization with Yttrium-90 (Y-90) beads is used to shrink liver tumors and reduce the tumor burden. However, a side effect of this treatment can be the shunting of Y-90 beads to the pulmonary circulation, leading to short-term radiation pneumonitis. While the short-term effects of hepatopulmonary shunting are well-defined, long-term complications have not been explored in the literature. We discuss the finding of multifocal interstitial pulmonary fibrosis in a patient treated with Y-90 for hepatocellular carcinoma. The reticular opacities were identified on chest CT scans seven months after the procedure and continued to consolidate up to 75 months post-radioembolization. Pathology confirmed multifocal fibrosis associated with Y-90 beads. This happened despite a low LSF and in the absence of clinical evidence of post-treatment radiation pneumonitis or chronic interstitial lung disease. This case report identifies radiation fibrosis as a differential diagnostic consideration when working up post-radioembolization patients with unexplained reticular opacities on lung imaging.
- 24 April 2025
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 33 (7) , 1686-1693
Long-Term Multifocal Pulmonary Fibrosis Associated with Y-90 Embolization: A Case Report and Literature Review
Radioembolization with Yttrium-90 (Y-90) beads is used to shrink liver tumors and reduce the tumor burden. However, a side effect of this treatment can be the shunting of Y-90 beads to the pulmonary circulation, leading to short-term radiation pneumonitis. While the short-term effects of hepatopulmonary shunting are well-defined, long-term complications have not been explored in the literature. We discuss the finding of multifocal interstitial pulmonary fibrosis in a patient treated with Y-90 for hepatocellular carcinoma. The reticular opacities were identified on chest CT scans seven months after the procedure and continued to consolidate up to 75 months post-radioembolization. Pathology confirmed multifocal fibrosis associated with Y-90 beads. This happened despite a low LSF and in the absence of clinical evidence of post-treatment radiation pneumonitis or chronic interstitial lung disease. This case report identifies radiation fibrosis as a differential diagnostic consideration when working up post-radioembolization patients with unexplained reticular opacities on lung imaging.
- Open Access
- 28 June 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-10
A panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes
Tumor-Infiltrating Lymphocytes (TILs) have strong prognostic and predictive value in breast cancer, but their visual assessment is subjective. To improve reproducibility, the International Immuno-oncology Working Group recently released recommendations for the computational assessment of TILs that build on visual scoring guidelines. However, existing resources do not adequately address these recommendations due to the lack of annotation datasets that enable joint, panoptic segmentation of tissue regions and cells. Moreover, existing deep-learning methods focus entirely on either tissue segmentation or cell nuclei detection, which complicates the process of TILs assessment by necessitating the use of multiple models and reconciling inconsistent predictions. We introduce PanopTILs, a region and cell-level annotation dataset containing 814,886 nuclei from 151 patients, openly accessible at: sites.google.com/view/panoptils. Using PanopTILs we developed MuTILs, a neural network optimized for assessing TILs in accordance with clinical recommendations. MuTILs is a concept bottleneck model designed to be interpretable and to encourage sensible predictions at multiple resolutions. Using a rigorous internal-external cross-validation procedure, MuTILs achieves an AUROC of 0.93 for lymphocyte detection and a DICE coefficient of 0.81 for tumor-associated stroma segmentation. Our computational score closely matched visual scores from 2 pathologists (Spearman R = 0.58–0.61, p < 0.001). Moreover, computational TILs scores had a higher prognostic value than visual scores, independent of TNM stage and patient age. In conclusion, we introduce a comprehensive open data resource and a modeling approach for detailed mapping of the breast tumor microenvironment.
- 28 June 2024
- Published by Springer Nature in npj Breast Cancer
- Vol. 10 (1) , 1-10
Open AccessA panoptic segmentation dataset and deep-learning approach for explainable scoring of tumor-infiltrating lymphocytes
Tumor-Infiltrating Lymphocytes (TILs) have strong prognostic and predictive value in breast cancer, but their visual assessment is subjective. To improve reproducibility, the International Immuno-oncology Working Group recently released recommendations for the computational assessment of TILs that build on visual scoring guidelines. However, existing resources do not adequately address these recommendations due to the lack of annotation datasets that enable joint, panoptic segmentation of tissue regions and cells. Moreover, existing deep-learning methods focus entirely on either tissue segmentation or cell nuclei detection, which complicates the process of TILs assessment by necessitating the use of multiple models and reconciling inconsistent predictions. We introduce PanopTILs, a region and cell-level annotation dataset containing 814,886 nuclei from 151 patients, openly accessible at: sites.google.com/view/panoptils. Using PanopTILs we developed MuTILs, a neural network optimized for assessing TILs in accordance with clinical recommendations. MuTILs is a concept bottleneck model designed to be interpretable and to encourage sensible predictions at multiple resolutions. Using a rigorous internal-external cross-validation procedure, MuTILs achieves an AUROC of 0.93 for lymphocyte detection and a DICE coefficient of 0.81 for tumor-associated stroma segmentation. Our computational score closely matched visual scores from 2 pathologists (Spearman R = 0.58–0.61, p < 0.001). Moreover, computational TILs scores had a higher prognostic value than visual scores, independent of TNM stage and patient age. In conclusion, we introduce a comprehensive open data resource and a modeling approach for detailed mapping of the breast tumor microenvironment.
- Top Cited Papers
- 27 November 2023
- Published by Springer Nature in Nature Medicine
- Vol. 30 (1) , 85-97
A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
Breast cancer is a heterogeneous disease with variable survival outcomes. Pathologists grade the microscopic appearance of breast tissue using the Nottingham criteria, which are qualitative and do not account for noncancerous elements within the tumor microenvironment. Here we present the Histomic Prognostic Signature (HiPS), a comprehensive, interpretable scoring of the survival risk incurred by breast tumor microenvironment morphology. HiPS uses deep learning to accurately map cellular and tissue structures to measure epithelial, stromal, immune, and spatial interaction features. It was developed using a population-level cohort from the Cancer Prevention Study-II and validated using data from three independent cohorts, including the Prostate, Lung, Colorectal, and Ovarian Cancer trial, Cancer Prevention Study-3, and The Cancer Genome Atlas. HiPS consistently outperformed pathologists in predicting survival outcomes, independent of tumor–node–metastasis stage and pertinent variables. This was largely driven by stromal and immune features. In conclusion, HiPS is a robustly validated biomarker to support pathologists and improve patient prognosis.
- 27 November 2023
- Published by Springer Nature in Nature Medicine
- Vol. 30 (1) , 85-97
Top Cited PapersA population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
Breast cancer is a heterogeneous disease with variable survival outcomes. Pathologists grade the microscopic appearance of breast tissue using the Nottingham criteria, which are qualitative and do not account for noncancerous elements within the tumor microenvironment. Here we present the Histomic Prognostic Signature (HiPS), a comprehensive, interpretable scoring of the survival risk incurred by breast tumor microenvironment morphology. HiPS uses deep learning to accurately map cellular and tissue structures to measure epithelial, stromal, immune, and spatial interaction features. It was developed using a population-level cohort from the Cancer Prevention Study-II and validated using data from three independent cohorts, including the Prostate, Lung, Colorectal, and Ovarian Cancer trial, Cancer Prevention Study-3, and The Cancer Genome Atlas. HiPS consistently outperformed pathologists in predicting survival outcomes, independent of tumor–node–metastasis stage and pertinent variables. This was largely driven by stromal and immune features. In conclusion, HiPS is a robustly validated biomarker to support pathologists and improve patient prognosis.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Whole-slide histology images contain information that is valuable for clinical and basic science investigations of cancer but extracting quantitative measurements from these images is challenging for researchers who are not image analysis specialists. In this article, we describe HistomicsML2, a software tool for learn-by-example training of machine learning classifiers for histologic patterns in whole-slide images. This tool improves training efficiency and classifier performance by guiding users to the most informative training examples for labeling and can be used to develop classifiers for prospective application or as a rapid annotation tool that is adaptable to different cancer types. HistomicsML2 runs as a containerized server application that provides web-based user interfaces for classifier training, validation, exporting inference results, and collaborative review, and that can be deployed on GPU servers or cloud platforms. We demonstrate the utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and cutaneous melanoma.Significance:An interactive machine learning tool for analyzing digital pathology images enables cancer researchers to apply this tool to measure histologic patterns for clinical and basic science studies.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Whole-slide histology images contain information that is valuable for clinical and basic science investigations of cancer but extracting quantitative measurements from these images is challenging for researchers who are not image analysis specialists. In this article, we describe HistomicsML2, a software tool for learn-by-example training of machine learning classifiers for histologic patterns in whole-slide images. This tool improves training efficiency and classifier performance by guiding users to the most informative training examples for labeling and can be used to develop classifiers for prospective application or as a rapid annotation tool that is adaptable to different cancer types. HistomicsML2 runs as a containerized server application that provides web-based user interfaces for classifier training, validation, exporting inference results, and collaborative review, and that can be deployed on GPU servers or cloud platforms. We demonstrate the utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and cutaneous melanoma.Significance:An interactive machine learning tool for analyzing digital pathology images enables cancer researchers to apply this tool to measure histologic patterns for clinical and basic science studies.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers